Cargando…
FoxO3a Inhibits Tamoxifen-Resistant Breast Cancer Progression by Inducing Integrin α5 Expression
SIMPLE SUMMARY: Tamoxifen is a mainstay of adjuvant treatment for estrogen receptor α-positive (ERα+) breast tumors, which account for over 70% of all the diagnosed breast malignancies. Unfortunately, ~30% of patients initially responding to the therapy will eventually relapse with an endocrine-resi...
Autores principales: | Ricci, Elena, Fava, Mariarosa, Rizza, Pietro, Pellegrino, Michele, Bonofiglio, Daniela, Casaburi, Ivan, Lanzino, Marilena, Giordano, Cinzia, Bruno, Rosalinda, Sirianni, Rosa, Barone, Ines, Sisci, Diego, Morelli, Catia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750403/ https://www.ncbi.nlm.nih.gov/pubmed/35008379 http://dx.doi.org/10.3390/cancers14010214 |
Ejemplares similares
-
FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer
por: Pellegrino, Michele, et al.
Publicado: (2019) -
DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation
por: Lanzino, M, et al.
Publicado: (2013) -
Androgens Modulate Bcl-2 Agonist of Cell Death (BAD) Expression and Function in Breast Cancer Cells
por: Morelli, Catia, et al.
Publicado: (2023) -
AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells
por: De Amicis, Francesca, et al.
Publicado: (2019) -
Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells—identification of a novel androgen response element
por: Lanzino, Marilena, et al.
Publicado: (2010)